Study of Triple-Negative Breast Cancer is Most Cited in AACR Journal
|
|
- Della Marsh
- 5 years ago
- Views:
Transcription
1 MEDIA CONTACT: Craig Civale (817) Study of Triple-Negative Breast Cancer is Most Cited in AACR Journal TGen, Baylor, US Oncology study revealed therapeutic drug targets for aggressive form of breast cancer DALLAS May 14, 2015 At its annual meeting, the American Association for Cancer Research (AACR) announced that a scientific paper describing potential drug targets following the unprecedented genomic sequencing of 14 metastatic triple-negative breast cancer patients was the most cited study in 2013 of any published that year by AACR s journal Molecular Cancer Therapeutics. In the study, genomic sequencing spelling out the billions of pieces of genetic information in an individual patient s DNA revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC). TGen, Baylor University Medical Center and US Oncology Research investigators found significant recurring mutations and other changes in more than a dozen genes in patients treated at Baylor University Medical Center at Dallas. In addition, the investigators identified mutations previously unseen in metastatic TNBC and took the sequencing data into account in selection of therapeutic protocols specific to each patient's genetic profile. The nature of this disease cried out for innovative research techniques such as whole genome sequencing coupled with new tools for data analysis, said Dr. David Craig, Ph.D., TGen's Deputy Director of Bioinformatics, one of the study's co-lead authors.
2 The most frequently mutated gene among the tumors was the TP53 tumor suppressor, and aberrations were observed in additional tumor suppressor genes including CTNNA1, which was detected in two of six African American patients. Alterations were also seen in the ERBB4 gene, known to be involved in mammary-gland maturation during pregnancy and lactation, but not previously linked to metastatic TNBC. Each tumor was genomically unique, but the majority contained alterations in one or both of the RAS/RAF/MEK/ERK and PI3K/AKT/MTOR pathways. Targeted therapeutic intervention aimed at these pathways achieved antitumor responses in several cases. The fact that this study has been cited more often than any other in Molecular Cancer Therapeutics that year is a testament to strong interest the oncology community has in understanding the molecular basis of metastatic TNBC, and in the hypothesis that targeting specific mutations in patients TNBCs will improve patients outcomes, said Joyce O'Shaughnessy, M.D., the study's other co-lead author. Dr. O'Shaughnessy is the Celebrating Women Chair of Breast Cancer Research at Baylor University Medical Center at Dallas, Chair of the US Oncology Network s Breast Cancer Program, and a practicing oncologist with Texas Oncology. Metastatic TNBC is a highly aggressive form of breast cancer that does not express the estrogen receptor, progesterone receptor or HER-2, the biomarkers successfully targeted in most breast cancers. Metastatic TNBC has a poor prognosis with a median survival rate among metastatic patients of only one year. While TNBC accounts for only about 15 percent of all breast cancers, its more aggressive biology makes it responsible for nearly one in four deaths related to this disease. This study continues to stand as a great example of molecular medicine in practice. The results have provided novel and interesting clues into breast cancer biology and into the promise and challenges of precision medicine, said Dr. John
3 Carpten, Ph.D., TGen's Deputy Director of Basic Science, Director of TGen's Integrated Cancer Genomics Division, and the study's senior author. The study, Genome and transcriptome sequencing in prospective triple negative breast cancer uncovers therapeutic vulnerabilities, was conducted by the Translational Genomics Research Institute (TGen) and US Oncology Research with support from Life Technologies Corporation. Molecular Cancer Therapeutics is one of several peer-reviewed scientific journals published by the 35,000-member American Association for Cancer Research (AACR), the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer. About TGen Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: About US Oncology Research Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in a variety of oncology clinical trials, including Phase I-Phase IV as well as observational trials. US Oncology
4 Research serves nearly 70 research sites and approximately 240 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 57,000 patients in nearly 1,300 trials since inception in 1992 and have played a role in 48 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information call (800) or visit About Texas Oncology Texas Oncology delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options available to help patients achieve More breakthroughs. More victories. in their fights against cancer. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with sites of service throughout Texas and southeastern Oklahoma. Texas Breast Specialists and Texas Urology Specialists, which focus on all areas of breast and urologic care, are a part of Texas Oncology. Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Texas Oncology, through its affiliation with US Oncology Research, has played a role in more than 50 FDA-approved cancer-fighting drugs, nearly one-third of all cancer therapies approved by the FDA to date. Texas Oncology is united in healing with The US Oncology Network, one of the nation s largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, Texas Oncology is united with more than 1,000 physicians and 10,000 cancer professionals nationwide. The US Oncology Network is supported by McKesson Specialty Health. For more information, visit or call I CAN (4226). About Baylor University Medical Center at Dallas
5 Baylor University Medical Center at Dallas, a 1025-bed not-for-profit academic hospital, is a major patient care and research center in the southwest. The nationally acclaimed medical center serves as the North Texas flagship hospital for Baylor Scott & White Health, the largest not-for-profit health care system in Texas. In addition to its Level 1 trauma center, Baylor Dallas is also home to many nationally ranked centers of excellence including transplant, cardiovascular services, orthopedics, digestive diseases, neurosciences, gynecology and oncology, including Baylor Charles A. Sammons Cancer Center. In 2014, U.S. News & World Report recognized Baylor Dallas 22nd consecutive year in its "America's Best Hospitals" guide. Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor University Medical Center at Dallas or Baylor Scott & White Health. # # #
Neurofibromatosis (NF) Center
Washington University Neurofibromatosis (NF) Center THE NF CENTER: EXCEPTIONAL CARE THROUGH GROUNDBREAKING RESEARCH An international leader in research and treatment of neurofibromatosis (NF), the Washington
More informationChildren s Research Institute
Children s Research Institute Children s National Health System Learning that a child has a serious health condition is devastating. Yet, no matter how dire a diagnosis may be, parents hold out hope that
More informationMaking a Difference. Highest quality care. Education. Research. Innovation. OUR MISSION:
Making a Difference Highest quality care. Education. Research. Innovation. OUR MISSION: To deliver world-class care on a daily basis to our patients using the most advanced technologies available. To conduct
More informationPartnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC The patients are waiting. Dr. Paul Janssen To Our Potential
More informationThomas C. Wilmot, Sr. Judy Wilmot Linehan
Thomas C. Wilmot, Sr. Judy Wilmot Linehan The Wilmot Family For more than 35 years, the Wilmot family has been dedicated to supporting cancer research and care for the Rochester community. Their generosity
More informationAn update on your support of the Kaplan Cancer Research Fund Swedish Cancer Institute
An update on your support of the Swedish Cancer Institute At Swedish, we re committed to offering our patients the newest, most innovative cancer treatment available. Through your support of the at the
More informationPROGRESS UPDATE. The Pan-Mass Challenge
PROGRESS UPDATE The Pan-Mass Challenge Fall 2017 PAN-MASS CHALLENGE: HITTING A HIGHER GEAR IN THE FIGHT AGAINST CANCER For nearly four decades, the Pan-Mass Challenge (PMC) and Dana- Farber Cancer Institute
More informationUnderstanding Tumor Markers for Breast and Colorectal Cancers. A Patient s Guide. Recommendations of the American Society of Clinical Oncology
Cover Layout 1 A Patient s Guide Understanding Tumor Markers for Breast and Colorectal Cancers Recommendations of the American Society of Clinical Oncology ... Cover Layout 2 A Patient s Guide Understanding
More informationCITY OF HOPE PROSTATE CANCER OUTCOME SUMMARY
CITY OF HOPE PROSTATE CANCER OUTCOME SUMMARY City of Hope s median survival surpasses SEER LA in Stages I IV Prostate Cancer* Surveillance, Epidemiology, and End Results Program *Based on SEER data from
More informationMelanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
More informationBaylor Scott & White Researchers Present Novel Findings at Digestive Disease Week 2016
MEDIA CONTACT: Megan Brooks Megan.Brooks@BSWHealth.org 214-820-7540 Baylor Scott & White Researchers Present Novel Findings at Digestive Disease Week 2016 From new biomarkers to advances in understanding
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationDIVISION OF NEPHROLOGY & HYPERTENSION
DIVISION OF NEPHROLOGY & HYPERTENSION DIVISION OF NEPHROLOGY & HYPERTENSION UH CASE MEDICAL CENTER Among the nation s leading academic medical centers, UH Case Medical Center is the primary affiliate of
More informationClaudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS
Claudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS Brain Cancer New Treatment Opportunities - Discovery of new pathways in brain cancers
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationWith your help, our goal is to protect millions more against serious illness through the development of new vaccines and other preventions.
Millions of children are alive, healthy, and have grown to productive adulthood because of what our scientists have taught the world through research. The Hib vaccine alone has saved more than 660,000
More information-- Kaiser Permanente Presents Results from Large Community-Based Study Consistent with NSABP Recurrence Study Findings
www.genomichealth.com Contacts: Kathleen Rinehart/GHI: 408/460-9116 Jim Weiss/GHI: 415/609-3680 Lori Garvey/NSABP: 412/330-4621 The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic
More informationGROUNDBREAKING FOCUS REVOLUTIONARY IMPACT
Cancer Research Institute One Exchange Plaza 55 Broadway, Suite 1802 New York, NY 10006 Phone: 212.688.7515 Toll Free: 800.99.CANCER www.cancerresearch.org @CancerResearch UNLEASHING THE POWER OF OUR OWN
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationGenitourinary Oncology Fellowship for Physicians in China A Multidisciplinary Clinical and Research Training Opportunity at Massachusetts General
Genitourinary Oncology Fellowship for Physicians in China A Multidisciplinary Clinical and Research Training Opportunity at Massachusetts General Hospital Cancer Center 2 Genitourinary Oncology Fellowship
More informationEmerging Issues in Food and Drug Law: Implementation of FDASIA Innovative Drug Approvals: Breakthrough Therapies Arnold & Porter LLP, Washington DC
Emerging Issues in Food and Drug Law: Implementation of FDASIA Innovative Drug Approvals: Breakthrough Therapies Arnold & Porter LLP, Washington DC Ryan M. Hohman, JD, MPA Managing Director, Friends of
More informationPROGRESS UPDATE. The Prayers From Maria Foundation
PROGRESS UPDATE The Prayers From Maria Foundation August 2016 EXECUTIVE SUMMARY Dana-Farber Cancer Institute is a global leader in discovery science and patient care for pediatric brain tumors, including
More informationSponsorship Opportunities I AM A RIDER. I AM THE DIFFERENCE. Hosted by. October 29, 2017
Sponsorship Opportunities I AM A RIDER. I AM THE DIFFERENCE. Hosted by October 29, 2017 Be a part of the 2017 Wheel to Survive Houston Wheel to Survive 2017 is Houston s second annual indoor cycling fundraiser
More informationSingle-Gene. NGS Sequencing Throughput 1 sample 48 Samples
For immediate release Hong Kong Sanatorium & Hospital State-of-the-Art Molecular Pathology Laboratory Introduces First-in-Hong Kong Next Generation Sequencing for Clinical Diagnostic Service (8 November
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationAmerican Cancer Society
American Cancer Society Breast Cancer Awareness for the Worksite HAP Worksite Wellness Forum October 18,2012 Melissa DiPirro Coordinator, Health Initiatives Official Sponsor of Birthdays Mission: We are
More informationCirculating Tumor Cells in non- Metastatic Triple Negative Breast Cancer
Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Carolyn Hall, Ph.D. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Triple Negative Breast Cancer
More informationOhio State Urology Update. New fellowship offering Research focus on pediatric UTIs Men s Sexual Health adds new service
Ohio State Urology Update New fellowship offering Research focus on pediatric UTIs Men s Sexual Health adds new service 3,185 SURGICAL CASES 2 FELLOWS Ohio State Urology by the Numbers OFFICE AND OUTPATIENT
More informationAACR JOURNAL PORTFOLIO MUST-HAVE CONTENT ANYTIME, ANYWHERE
AACR JOURNAL PORTFOLIO MUST-HAVE CONTENT ANYTIME, ANYWHERE 2016 American Association for Cancer Research WHO WE ARE Founded in 1907 Oldest and largest scientific organization focused on cancer research
More informationYour Guide to Prostate Cancer
Your Guide to Prostate Cancer If you face a diagnosis of prostate cancer, what s next? We can help. A prostate cancer diagnosis can be overwhelming. The good news is that while prostate cancer can be serious,
More informationDONOR RECOGNITION PROGRAM
DONOR RECOGNITION PROGRAM HARLEY S ANGELS CRUIZIN TO CURE Mission Statement The Mission of Harley's Angels is to promote breast cancer awareness, education, and support of research for the prevention and
More informationOpportunity and Challenge
Opportunity and Challenge Implementation of Comparative Effectiveness Research: The Patient Protection and Affordable Care Act Dr. Ellen V. Sigal, Chair & Founder, Friends of Cancer Research Comparative
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationDONNA BOWERS & ALAN MILLER
BAYLOR HEALTH CARE SYSTEM ONCOLOGY NETWORK NEWS UPDATE WITH YOUR BHCS ONCOLOGY ANCHORS DONNA BOWERS & ALAN MILLER 1 The Evolution of Cancer Care Slash, burn and poison era Precision Medicine Casting out
More informationExtraordinary service, far from ordinary
Signature Services Premier International Health Extraordinary service, far from ordinary Why Choose Lenox Hill Hospital International Health? Lenox Hill Hospital is the care destination of choice for more
More informationUROLOGY. Innovation in Bladder Cancer Treatment CHICAGO ACCESS. How to Refer a Patient. Clinical Trials at UChicago Medicine: Ask Us More Questions!
Clinical Trials at UChicago Medicine: UNIVERSITY OF MEDICINE Department of Surgery 5841 South Maryland Avenue, MC 3026 Chicago, IL 60637 FALL 2015 REFERRING PHYSICIAN NE WSLE T TER FROM THE UNIVERSIT Y
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationCatherine Ivy. A Foundation of Devotion. london flys bentley roadtrip fender. DECEMBER 2012 VOLUME 10 ISSUE 12
DECEMBER 2012 VOLUME 10 ISSUE 12 www.frontdoorsnews.com Catherine Ivy A Foundation of Devotion SUBSCRIBE TO THE MAGAZINE london flys bentley roadtrip fender A Path of Philanthrop cover story Tragedy to
More informationTHE UC SANTA CRUZ GENOMICS INSTITUTE. David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director
THE UC SANTA CRUZ GENOMICS INSTITUTE David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director April 8, 2015 OUR MISSION Unlocking the world s genomic data to accelerate medical
More informationR e s e a r c h S t r a t e g y
Sheffield Teaching Hospitals NHS Foundation Trust Academic Directorate of Urology R e s e a r c h S t r a t e g y Academic Directorate of Urology Research Strategy Contents 1. Executive Summary 2. Current
More informationCancer Control from the Community Oncology Perspective
Cancer Control from the Community Oncology Perspective Lee Schwartzberg MD, FACP Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science Center IOM Report
More informationParkinson s Research and the New Centre for Brain Health at UBC. Case for Support The University of British Columbia Faculty of Medicine
Parkinson s Research and the New Centre for Brain Health at UBC Case for Support The University of British Columbia Faculty of Medicine THE VALUE OF A HEALTHY BRAIN By 2020, brain disease will overtake
More informationFinding the Positives in Triple-Negative Breast Cancer:
Finding the Positives in Triple-Negative Breast Cancer: A Three-Part Live CME Webcast Series Seminar I Wednesday, March 3, 2010 Faculty Clifford Hudis, MD Lisa A Carey, MD Seminar II Thursday, March 11,
More informationThe Case for a Vascular Surgery Review Committee. John F Eidt MD Baylor University Medical Center Dallas, Texas
The Case for a Vascular Surgery Review Committee John F Eidt MD Baylor University Medical Center Dallas, Texas Disclosures Senior Director of the American Board of Surgery The opinions expressed today
More informationRSRT Awards $10 Million to Preeminent Researchers in Pursuit of Curing Devastating Neurological Disorder
P R E S S R E L E A S E RSRT Awards $10 Million to Preeminent Researchers in Pursuit of Curing Devastating Neurological Disorder September 25, 2018 Media Contacts: Monica Coenraads Executive Director,
More informationEXCELLENCE AND INNOVATION
EXCELLENCE AND INNOVATION FOR CANCER TREATMENT THE CENTRE LÉON BÉRARD Non-profit private health care facility of public interest (ESPIC), affiliated with the French National Cancer Center Federation UNICANCER
More informationTransplantUpdate. A Report From Baylor Regional Transplant Institute Volume 1 Number 4
TransplantUpdate A Report From Baylor Regional Transplant Institute Volume 1 Number 4 Alcoholic Liver Disease 2 Alcoholic liver disease is the second leading indication for liver transplantation in the
More informationR e s e a r c h S t r a t e g y
Sheffield Teaching Hospitals NHS Foundation Trust Academic Directorate of Specialised Cancer R e s e a r c h S t r a t e g y Academic Directorate of Specialised Cancer Research Strategy Executive Summary
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationSurgery saved my life. Rehab is restoring my future.
The Best Way Back Baylor Institute for Rehabilitation offers care for the most challenging and medically complex patients, including those with traumatic brain injury, traumatic spinal cord injury and
More informationI tell my patients, If I can do it, you can do it. Lea Stewart
I tell my patients, If I can do it, you can do it. Lea Stewart Baylor Institute for Rehabilitation Lea Stewart A traffic accident threw Lea Stewart around the back of a pick-up truck, leaving the life-long
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationYour Excellency, Mr Paul Madden, British High Commissioner, Singapore. It is a great pleasure to welcome all of you to the Biopolis for this two-day
OPENING SPEECH BY MR LIM CHUAN POH, CHAIRMAN, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, AT THE UK-SINGAPORE SYMPOSIUM ON P53: THE NEXT 30 YEARS, 25 NOVEMBER 2009 @ 0900HRS @ BREAKTHROUGH THEATRETTE,
More informationExcellence Without Exception
Excellence Without Exception The Eastman Institute for Oral Health (EIOH) at the University of Rochester is unique among academic health centers in the United States. Despite the absence of an undergraduate
More informationI tell my patients, If I can do it, you can do it. Lea Stewart
I tell my patients, If I can do it, you can do it. Lea Stewart Baylor Institute for Rehabilitation Lea Stewart A traffic accident threw Lea Stewart around the back of a pick-up truck, leaving the life-long
More informationUC San Diego HIV Institute Creating a Future Without HIV/AIDS
UC San Diego HIV Institute Creating a Future Without HIV/AIDS Executive Summary HIV/AIDS will never cure itself, but at the University of California San Diego and UC San Diego Health, we believe that we
More informationBrain Tumour Initiative: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research supported by:
Brain Tumour Initiative: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research supported by: We remain extremely grateful to the Alison Fracella Research Trust for the support given
More informationScience Report ADVANCES IN CANCER RESEARCH
Science Report ADVANCES IN CANCER RESEARCH Created by Huntsman Cancer Institute s Office of Communications 2016 www.huntsmancancer.org OUR TIME BEGAN with an empty lot and a dream full of promise, determination,
More informationPROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund
PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund October 2017 EXECUTIVE SUMMARY Investigators at Dana-Farber Cancer Institute are global leaders in pediatric brain tumor research and patient care,
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationEasy Breathing. An asthma management program for Pediatricians, Primary Care Practitioners, and Family Practitioners.
Easy Breathing An asthma management program for Pediatricians, Primary Care Practitioners, and Family Practitioners. The Asthma Center The Asthma Center at Connecticut Children s Medical Center was established
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationLEVINE CANCER INSTITUTE. Brand Articulation and Messaging Platform
LEVINE CANCER INSTITUTE Brand Articulation and Messaging Platform CONTENTS: Overview/Rationale X Potential Core Brand Values X Brand Attributes X Brand Personality X Brand Positions X The primary purpose
More informationAUSTRALIA'S ONLY DEDICATED ACADEMIC DEPARTMENT OF NEUROSCIENCE.
AUSTRALIA'S ONLY DEDICATED ACADEMIC DEPARTMENT OF NEUROSCIENCE www.monash.edu/medicine/ccs/neuroscience Ocular motor testing is important as an overall measure of brain function 2 MONASH UNIVERSITY DEPARTMENT
More informationMeeting California s Cancer Challenges. UC Cancer Consortium
Meeting California s Cancer Challenges UC Cancer Consortium 2017 Despite steady declines in cancer rates over the past 20 years, cancer is soon expected to overtake heart disease as California s leading
More informationPhase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint
For immediate release: April 15, 2015 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Announces PALOMA-3 Trial for IBRANCE (Palbociclib) Stopped Early Due
More informationAn Extraordinary Resource for Cancer Care
An Extraordinary Resource for Cancer Care Anderson Family Cancer Institute The Campaign for Jupiter Medical Center Gaining Critical Mass Against Cancer $50 Million fundraising goal to build our new cancer
More informationYale Center For Clinical Investigation. Internship Program. Join Our Growing Team and Help Us Discover. Yale
Center For Clinical Investigation Internship Program Join Our Growing Team and Help Us Discover Moving Science Forward Local teens take the artificial pancreas for a test run at City Climb Gym in New Haven.
More informationASTELLAS AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
Astellas Contact: Medivation Contacts: For Media For Media Tyler Marciniak Samina Bari Director, Communications Vice President, Corporate (847) 736-7145 Communications tyler.marciniak@astellas.com (415)
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationTestimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and
Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and The Society for Healthcare Epidemiology of America (SHEA) to the U.S. House of Representatives Appropriations
More informationDiversity Clinical Research Workshop Invited Faculty
Diversity Clinical Research Workshop Invited Faculty Alex A. Adjei, MD, PhD, FACP Professor and Chair, Department of Medicine Senior Vice President of Clinical Research The Katherine Anne Gioia Chair in
More informationMarch 8, Written Testimony for FY 2018 Appropriations for the Department of Health and Human Services
AMERICAN GERIATRICS SOCIETY Written Testimony for the Record Fiscal Year 2018 Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies Committee on Appropriations
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationFigure 1. Image of Heat Shock Protein 90, A Molecular Chaperone, Which Is Inhibited in Cancer Cells by Ganetespib Preventing Cell Growth.
Synta's Anti-Cancer Therapy Data Extremely Positive And More Upside Is Likely Jul 30 2013 Cancer is disease that has impacted the lives of each and everyone one of us. Yesterday Synta Pharmaceuticals (SNTA)
More informationABOUT THE CLAHRC. South London
Collaboration for Leadership in Applied Health Research and Care South London (CLAHRC South London) ABOUT THE CLAHRC South London l The Collaboration for Leadership in Applied Health Research and Care
More informationI. CHESTER COUNTY COMMUNITY FOUNDATION GRANT PROPOSAL SUMMARY SHEET Date September 20, 2018
Contact Information Organization Name: AACR Foundation established to support the American Association for Cancer Research (AACR) Address: 615 Chestnut Street 17 th Floor Philadelphia, PA 19106 Phone:
More informationStrategic Plan
Strategic Plan 2013-2018 Strategic Plan 2013-2018 Contents The Challenges of an Aging Population.. Baycrest: fulfilling a legacy of commitment and accomplishment Looking Ahead: dedicated to serve our local
More informationRESEARCHERS FROM A*STAR AND NUS IMPLICATE HOUSE DUST MITES AS THE MAIN CAUSE OF RESPIRATORY ALLERGIES IN SINGAPORE
MEDIA RELEASE 07 Feb 2014 RESEARCHERS FROM A*STAR AND NUS IMPLICATE HOUSE DUST MITES AS THE MAIN CAUSE OF RESPIRATORY ALLERGIES IN SINGAPORE Study findings provide a basis for developing effective allergy
More informationAffiliate Highlight: Fellow Gains New Perspective on the Impact of Breast Cancer Research
Page 1 of 5 Share Past Issues Komen Research Updates 2013 ASCO Annual Meeting, Exciting Research Grantee Announcements, and more! Table of Contents: Affiliate Highlight: Fellow Gains New Perspective on
More informationResearch goal is to identify better diagnostic, vaccine and treatment targets for chlamydia and gonorrhea
FOR IMMEDIATE RELEASE Contact: Chris Hardwick SOM Office of Public Affairs 410-706-5260 UNIVERSITY OF MARYLAND SCHOOLS OF DENTISTRY AND MEDICINE RECEIVE $10.7M GRANT TO CONDUCT SYSTEMS BIOLOGY RESEARCH
More informationMr. Kevin Dwan. The Sabrina Foundation Center for Cardiovascular Health in Pregnancy
A Proposal to Mr. Kevin Dwan For support of The Sabrina Foundation Center for Cardiovascular Health in Pregnancy A Proposal for the Support of The Sabrina Foundation Center for Cardiovascular Health in
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationTransatlantic Dream Team of Top Researchers Selected To Tackle One of Cancer s Deadliest Forms: Pancreatic Cancer
Transatlantic Dream Team of Top Researchers Selected To Tackle One of Cancer s Deadliest Forms: Pancreatic Cancer Stand Up To Cancer, Cancer Research UK, and The Lustgarten Foundation Fund Team with $12
More informationMurtha Cancer Center The DoD Cancer Center of Excellence
Accelerating Progress against Cancer through Collaboration Center of Excellence Oversight Board September 10, 2013 Colonel Craig D. Shriver, MC, USA. FACS Director 1 Summary Murtha Cancer Center Overview
More informationSINGAPORE SCIENTISTS DISCOVER NEW PATHWAYS LEADING TO CANCER PROGRESSION
MEDIA RELEASE FOR IMMEDIATE RELEASE 18 JULY 2016 SINGAPORE SCIENTISTS DISCOVER NEW PATHWAYS LEADING TO CANCER PROGRESSION SINGAPORE Scientists from A*STAR s Genome Institute of Singapore (GIS) and the
More informationHR 95% Confidence Interval. *no DFS events occurred in AJCC 7 stage I/II TNBC patients treated with NPS plus trastuzumab.
NEWS RELEASE SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2018 San Antonio Breast Cancer
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationABOUT LUNG CANCER ALLIANCE
ABOUT LUNG CANCER ALLIANCE www.lungcanceralliance.org 1-800-298-2436 WHO WE ARE Lung Cancer Alliance serves and listens to those living with and at risk for lung cancer to reduce stigma, improve quality
More informationPRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER
PRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER This collaboration creates the world s first clinically reliable and
More informationBoston Scientific is advancing...
Boston Scientific is advancing... Our mission Our values Boston Scientific is dedicated to transforming lives through innovative Caring Meaningful Innovation High Performance medical solutions that improve
More informationHEMATOLOGY AND ONCOLOGY
x THE POWER OF HEMATOLOGY AND ONCOLOGY Experts. Experience. Execution. A Deeper Dive into Hematology and Oncology Medpace supports our sponsors who are advancing new anti-cancer therapies by providing
More informationAcademic Critical Care Medicine. University of Alberta
Academic Critical Care Medicine University of Alberta Established Specialty Critical Care Medicine now embodies a unique body of knowledge of the epidemiology, assessment, treatment and outcomes of critical
More informationXstrahl designs and delivers effective clinical and research solutions to advance radiation oncology
Xstrahl designs and delivers effective clinical and research solutions to advance radiation oncology Xstrahl is a leading designer and manufacturer of superficial orthovoltage medical X-ray systems used
More informationCorrespondence should be addressed to Alicia McMaster;
Cancer Research Volume 2013, Article ID 308236, 5 pages http://dx.doi.org/10.1155/2013/308236 Research Article Taxpas: Epidemiological and Survival Data in Breast Cancer Patients Treated with a Docetaxel-Based
More informationFoundation Update... Fall 2005
GERALD P. MURPHY CANCER FOUNDATION Defeating Cancer through Basic, Comparative, and Clinical Research 3000 Kent Avenue, Suite E2-100 West Lafayette, IN-47906 Phone (765) 775-1005 Fax (765) 775-1006 Foundation
More informationTHE BENEFITS THE PARTNERS WHAT IS IMMUNOTHERAPY? HOW WILL IT WORK? WHY CANCER RESEARCH INSTITUTE? WHY ISRAEL CANCER RESEARCH FUND?
A groundbreaking, collaborative campaign bringing together the Cancer Research Institute, the leading nonprofit funder of immunotherapy research internationally, with the Israel Cancer Research Fund, North
More informationResidency and Fellowship Training
VA N D E R B I LT P S YC H I AT R Y A N D B E H AV I O R A L S C I E N C E S Residency and Fellowship Training W E L C O M E F R O M T H E C H A I R Psychiatry is changing. The emergence of new knowledge
More informationLeading-edge cancer treatment + compassionate care
CARE + COVERAGE ˡ NORTHERN CALIFORNIA Leading-edge cancer treatment + compassionate care Working together to bring you hope and healing When you hear the word cancer, it can be a frightening, confusing
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More information